Work

Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.2507

Authors: Michael S. Gordon, John J. Nemunaitis, Ramesh K. Ramanathan, George W. Sledge, Lan Wang, Xiaolin Fan, Monica Motwani, Shekman Wong, Susan Morgan-Lappe, Suhasini Iyer, Louie Naumovski, John H. Strickler

Institutions: HonorHealth, Pinnacle Oncology Hematology, Mary Crowley Cancer Research Center, Mayo Clinic, Mayo Clinic in Arizona, Stanford Medicine, Stanford University, AbbVie Biotherapeutics (United States), AbbVie (United States), Duke Medical Center

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2667592056

Cites:

Cited by: 4

Related to: 10